Canada’s AbCellera Biologics and US-based company Pfizer have collaborated, whereby the former will discover function-modulating antibodies against undisclosed membrane protein targets using its monoclonal antibody (mAb) screening platform.
The new multi-year, therapeutic antibody discovery collaboration is aimed at generating lead antibody candidates against membrane targets with the help of the mAb discovery platform.
AbCellera founding CEO Carl Hansen said: “Our platform allows us to screen natural immune repertoires with unparalleled depth to unlock the most challenging discovery programmes.
“This partnership reinforces our commitment to offer leading-edge antibody discovery capabilities and to create value for companies by providing access to our platform. We welcome the opportunity to work closely with the innovative team at Pfizer and look forward to building a lasting relationship.”
Under the agreement, the company will receive an upfront payment, as well as research support.
It will also be eligible to receive approximately $90m in contingent milestone payments.
Based on Pfizer’s development and commercialisation of antibodies that may be generated under this collaboration, AbCellera will be eligible for tiered mid-to-low single digit royalty payments.
Pfizer Biomedicines Design vice-president Will Somers said: “We are pleased to work with the team at AbCellera using their innovative antibody discovery platform.
“We hope this platform can aid in our research as we look to bring novel medicines to patients, seeking to discover modulators of a transmembrane protein in a therapeutically important target class.”
AbCellera’s single cell antibody discovery platform provides the ability to pharmaceutical and biotechnology partners to identify mAb therapeutic candidates from the natural immune repertoires of any species.
Image: The entrance to Pfizer World Headquarters in Manhattan, New York, US. Photo: courtesy of Coolcaesar.